| Not Yet Recruiting | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tu NCT07473726 | Shanghai Henlius Biotech | Phase 1 |
| Not Yet Recruiting | Immunotherapy Master Trial for Advanced Cancers NCT07431073 | UNICANCER | Phase 2 |
| Not Yet Recruiting | Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX NCT07480681 | Shanghai Henlius Biotech | Phase 1 |
| Recruiting | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors NCT07274813 | Shanghai Henlius Biotech | EARLY_Phase 1 |
| Recruiting | A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors NCT07141706 | DualityBio Inc. | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors NCT06922357 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors NCT07415863 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of MHB088C for Patients With Advanced Solid Malignant Tumors NCT07102004 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors NCT05718895 | Antengene Biologics Limited | Phase 1 |
| Recruiting | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma NCT05607498 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors NCT05614258 | Adagene Inc | Phase 1 |
| Unknown | A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors NCT05394168 | Shanghai Henlius Biotech | Phase 1 |
| Completed | Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic NCT05514444 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors NCT05425602 | Maxinovel Pty., Ltd. | Phase 1 / Phase 2 |
| Recruiting | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors NCT05405595 | Adagene Inc | Phase 1 / Phase 2 |
| Completed | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors NCT05277402 | Adagene Inc | Phase 1 |
| Active Not Recruiting | A Study of FDA018-ADC in Patients With Advanced Solid Tumors NCT05174637 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metast NCT04645069 | Adagene Inc | Phase 1 / Phase 2 |
| Completed | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors P NCT04501276 | Adagene Inc | Phase 1 |
| Terminated | Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors NCT04182516 | Nerviano Medical Sciences | Phase 1 |
| Terminated | Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metas NCT03833427 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors NCT03526835 | Merus B.V. | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicre NCT02665416 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors NCT02444793 | Pfizer | Phase 1 |
| Terminated | Study of NMS-1116354 in Advanced/Metastatic Solid Tumors NCT01092052 | Nerviano Medical Sciences | Phase 1 |
| Terminated | Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors NCT00996255 | Nerviano Medical Sciences | Phase 1 |